TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12684572

Group type: EXPERIMENTAL
Intervention: Daily supplementation with antioxidant vitamins and minerals at nutritional doses
Number of subjects: 13535

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13535
Study: 10593774

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 48
Study: 8910181

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both anesthesia types
Number of subjects: 100
Study: 1817626

Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine 45 ml (168.75 mg) with adrenaline 1 in 200,000
Number of subjects: 22

Group type: COMPARATOR
Intervention: Plain solution (bupivacaine without adrenaline)
Number of subjects: 22
Study: 7183202

Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 32
Study: 30607986

Group type: EXPERIMENTAL
Intervention: Precast adjustable compression system
Number of subjects: 42

Group type: COMPARATOR
Intervention: Multilayered compression bandages
Number of subjects: 42
Study: 28883183

Group type: EXPERIMENTAL
Intervention: handoverEHR (electronic handover tool)
Number of subjects: 32
Study: 25469463

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10 or 20 μg/day)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 24705731

Group type: EXPERIMENTAL
Intervention: Alvarado score (group A)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Clinical judgment (group B)
Number of subjects: 269
Study: 23021465

Group type: EXPERIMENTAL
Intervention: Closure of the tonsillar fossa using 3‐0 chromic sutures on tapered needles.
Number of subjects: 763

Group type: COMPARATOR
Intervention: Tonsillar fossa left open (control group).
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Tonsillar fossa closed.
Number of subjects: 763
Study: 19598336

Group type: EXPERIMENTAL
Intervention: Marsupialization
Number of subjects: 212

Group type: COMPARATOR
Intervention: Silver nitrate application
Number of subjects: 212
Study: 17464256

Group type: EXPERIMENTAL
Intervention: Computer-assisted diagnosis (CAD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Without CAD (combined readings of radiologists)
Number of subjects: 30
Study: 15257046

Group type: EXPERIMENTAL
Intervention: Daclizumab (1 mg/kg on days 0 and 10 after transplantation; steroid-free group n=186)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Prednisone (0.3 mg/kg per day tapered to 0 mg at week 16 after transplantation; steroids group n=178)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Comparison of steroid-free versus steroids at 3 months
Number of subjects: 364

Group type: COMPARATOR
Intervention: Comparison of steroid-free versus steroids at 12 months
Number of subjects: 364
Study: 12510471

Group type: EXPERIMENTAL
Intervention: Prompted voiding (PV)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care attention control
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prompted voiding (PV) after crossover
Number of subjects: 19
Study: 9525435

Group type: EXPERIMENTAL
Intervention: Cidofovir 5 mg/kg once weekly for 2 weeks, then maintenance therapy with 5 mg/kg once every other week
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cidofovir 3 mg/kg once every other week
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cidofovir therapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cidofovir
Number of subjects: 150
Study: 7893034

Group type: EXPERIMENTAL
Intervention: 0.3 mg of clonidine per os (PO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg) and vecuronium (0.15 mg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Desflurane (3.6% to 11%)
Number of subjects: 15
Study: 2305060

Group type: EXPERIMENTAL
Intervention: Two-screen workstation (1,000-line monitors, 12-bit dynamic range)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Film panel alternator
Number of subjects: 4
Study: 344899

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 191827

Group type: COMPARATOR
Intervention: Unvaccinated control group
Number of subjects: 191827
Study: 31668003

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03% ointment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03% ointment and microdermabrasion
Number of subjects: 35

Group type: COMPARATOR
Intervention: Petrolatum (placebo)
Number of subjects: 35
Study: 30912222

Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg/d
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/d
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg/d
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study: 28922397

Group type: EXPERIMENTAL
Intervention: Blue light exposure (n = 12)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amber light exposure (n = 18)
Number of subjects: 30
Study: 25583753

Group type: EXPERIMENTAL
Intervention: Otelixizumab
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23106511

Group type: EXPERIMENTAL
Intervention: FDIS+metronidazole
Number of subjects: 184

Group type: COMPARATOR
Intervention: FDIS+placebo
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: SRP+metronidazole
Number of subjects: 184

Group type: COMPARATOR
Intervention: SRP+placebo
Number of subjects: 184
Study: 20808147

Group type: EXPERIMENTAL
Intervention: Integrative reactivation and rehabilitation (IRR)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 168
Study: 19968048

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16715687

Group type: EXPERIMENTAL
Intervention: Short duration regimen (60 mg per day tapered over 12 weeks)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Low dose regimen (30 mg per day tapered over 20 weeks)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: High dose regimen (60 mg per day tapered over 20 weeks)
Number of subjects: 334
Study: 15478760

Group type: EXPERIMENTAL
Intervention: Parity judgment task with large numbers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parity judgment task with small numbers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Number magnitude judgment task
Number of subjects: 0
Study: 11547070

Group type: EXPERIMENTAL
Intervention: Periprostatic infiltration with 1% lidocaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intrarectal instillation of 2% lidocaine gel
Number of subjects: 150
Study: 9337437

Group type: EXPERIMENTAL
Intervention: Sequential intravenous‐to‐oral ofloxacin
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard intravenous‐to‐oral switch therapy
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard switch therapy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Sequential ofloxacin therapy
Number of subjects: 89
Study: 7835811

Group type: EXPERIMENTAL
Intervention: Conservative surgery
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cisplatin (adjuvant treatment)
Number of subjects: 99

Group type: COMPARATOR
Intervention: 32P (adjuvant treatment)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Observation (adjuvant treatment)
Number of subjects: 99
Study: 3680564

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) dextromethorphan (DM) suspension 60 mg bid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Immediate-release (IR) DM solution 30 mg qid
Number of subjects: 24
Study: 31786954

Group type: EXPERIMENTAL
Intervention: Trunk muscle endurance (measured by Timed Loaded Standing Test)
Number of subjects: 31
Study: 29343507

Group type: EXPERIMENTAL
Intervention: apremilast 30 mg twice daily
Number of subjects: 219

Group type: COMPARATOR
Intervention: apremilast
Number of subjects: 219
Study: 26787794

Group type: COMPARATOR
Intervention: Forced-air warming (n=78)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Resistive heating (n=82)
Number of subjects: 160
Study: 25910532

Group type: EXPERIMENTAL
Intervention: remifentanil (0.4 μg/kg per minute) and ketamine (5 μg/kg per minute)
Number of subjects: 56

Group type: COMPARATOR
Intervention: remifentanil (0.4 μg/kg per minute) and saline solution
Number of subjects: 56
Study: 22981952

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (10^8 colony‐forming units), n = 40, orally, in 5 drops, 1 time daily, for 21 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo, n = 40, orally, in 5 drops, 1 time daily, for 21 days
Number of subjects: 80
Study: 20350523

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg at 12 h pre-PCI and 40 mg at 2 h pre-PCI, followed by atorvastatin 40 mg/day for 30 days post-PCI
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care including atorvastatin 40 mg/day for 30 days post-PCI
Number of subjects: 350
Study: 18218826

Group type: EXPERIMENTAL
Intervention: Vibration exercise training (VIB) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercise without vibration training (EX) group
Number of subjects: 30
Study: 16830258

Group type: EXPERIMENTAL
Intervention: Baseline HRQL scores > median
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-week change in HRQL > median
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in FACT-P Grand Total Score > median
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline or 12-week change in HRQL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater deterioration in HRQL
Number of subjects: 0
Study: 12860331

Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum positive cultures (>10(5) cfu/ml) in endometritis patients (39% of 67 patients)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (women without endometritis)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Prevalence of parvo biovar
Number of subjects: 97
Study: 12454514

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 269

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 269
Study: 9800017

Group type: EXPERIMENTAL
Intervention: Video teaching
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lecture accompanied by slides
Number of subjects: 16
Study: 8181026

Group type: EXPERIMENTAL
Intervention: Nonglycosidic adrenergic and nonadrenergic inotropic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonglycosidic inotropic drugs (vesnarinone and ibopamine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adrenergic agents and phosphodiesterase inhibitors
Number of subjects: 0
Study: 2659235

Group type: EXPERIMENTAL
Intervention: Piperacillin and amikacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipenem and placebo
Number of subjects: 0
Study: 4938244

Group type: EXPERIMENTAL
Intervention: Thiopropazate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31849248

Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Number of subjects: 0
Study: 28666080

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) at a standard dose (200 mg every 2 weeks plus optimized methotrexate)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) at a reduced frequency (200 mg every 4 weeks plus MTX)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (CZP stopped)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) at a standard dose
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) at a reduced frequency
Number of subjects: 293
Study: 25607594

Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 150
Study: 23328304

Group type: COMPARATOR
Intervention: 4-galactosylxylose (gaxilose) at doses of 0.45 g for urine tests and 2.7 g for blood tests
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20549321

Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (TA1) 3.2 mg twice per day for 7 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional therapy for SAP
Number of subjects: 24
Study: 18654774

Group type: EXPERIMENTAL
Intervention: mini‐midvastus approach
Number of subjects: 70

Group type: COMPARATOR
Intervention: medial parapatellar arthrotomy
Number of subjects: 70
Study: 17448266

Group type: EXPERIMENTAL
Intervention: Calcium with or without vitamin D therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium with vitamin D therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen, selective estrogen receptor modulators (SERMs), and bisphosphonates (when given in combination with calcium and vitamin D)
Number of subjects: 0
Study: 14983226

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Regular-dose aprotinin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11795347

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9459084

Group type: EXPERIMENTAL
Intervention: 3.75 mg i.m. leuprolide acetate (LA) every 4 weeks for 24 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3.7 mg LA combined with 1.25 mg oral conjugated equine estrogen (CEE) and 5 mg oral medroxyprogesterone acetate (MA)
Number of subjects: 40
Study: 7934712

Group type: EXPERIMENTAL
Intervention: Extensive Explanation (EE)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Limited Explanation (LE)
Number of subjects: 136
Study: 2455176

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nifedipine (30 mg/day)
Number of subjects: 21
Study: 31156221

Group type: EXPERIMENTAL
Intervention: neuroleptic therapy in combination with intravenous infusions of remaxol (400.0 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: active placebo (0.9% sodium chloride solution, 400.0 ml)
Number of subjects: 60
Study: 27956428

Group type: EXPERIMENTAL
Intervention: MEDI8897 (300, 1,000, or 3,000 mg intravenously or 100 or 300 mg intramuscularly)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: MEDI8897 (300 mg i.m.)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: MEDI8897 (i.m. dosing)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: MEDI8897
Number of subjects: 136
Study: 26115690

Group type: EXPERIMENTAL
Intervention: Pulsed high-intensity laser therapy (HILT) plus routine physical therapy program (RPTP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo laser plus routine physical therapy program (RPTP)
Number of subjects: 61
Study: 23557930

Group type: EXPERIMENTAL
Intervention: GSK1322322 (500-1500 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: GSK1322322 (1000-1500 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: GSK1322322
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 21747084

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5) and pemetrexed (500 mg/m(2)) every 21 days for four cycles and thoracic radiation therapy (TRT) (70 Gy)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Carboplatin (AUC 5) and pemetrexed (500 mg/m(2)) every 21 days for four cycles and thoracic radiation therapy (TRT) (70 Gy) with cetuximab administered concurrent only with TRT
Number of subjects: 101
Study: 19573486

Group type: EXPERIMENTAL
Intervention: Lithium treatment (target serum level of lithium 0.5‐0.8 mmol/L)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 16451765

Group type: EXPERIMENTAL
Intervention: Non-hygiene side (NH)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Hygiene side (H)
Number of subjects: 39
Study: 15248052

Group type: EXPERIMENTAL
Intervention: New Carisolv gel (higher concentration of sodium hypochlorite)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Original Carisolv gel
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: New Carisolv gel
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Chemomechanical treatment (both gels)
Number of subjects: 170
Study: 11391598

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (Arm B): 2-3 cycles of cisplatin (100 mg/m2 on Day 1) and 5-fluorouracil (1000 mg/m2 per day continuous infusion on Days 1-5)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Surgery alone (Arm A): transthoracic esophagectomy plus two-field lymphadenectomy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (Arm B) with pathologic complete response
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (Arm B) with partial response
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (Arm B) responders vs nonresponders
Number of subjects: 48
Study: 9258754

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (400 IU daily for at least 2 years)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 8235809

Group type: EXPERIMENTAL
Intervention: Exercise therapy with advice for daily life by a physiotherapist
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo ultrasound therapy by a physiotherapist
Number of subjects: 473

Group type: COMPARATOR
Intervention: Usual care by the general practitioner
Number of subjects: 473
Study: 3321756

Group type: EXPERIMENTAL
Intervention: 300 mg Ibuprofen q.i.d. as pellets
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 600 mg Ibuprofen b.i.d. as dragees
Number of subjects: 10
Study: 31940011

Group type: EXPERIMENTAL
Intervention: Family-Focused Therapy (FFT) - 12 sessions in 4 months of psychoeducation, communication training, and problem-solving skills training
Number of subjects: 127

Group type: COMPARATOR
Intervention: Enhanced Care - 6 sessions in 4 months of family and individual psychoeducation
Number of subjects: 127
Study: 30261917

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (specific dosage not mentioned) administered over 6 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (most promising dose from stage 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Objective measures including facial expression recognition, cerebrospinal fluid (CSF) oxytocin levels, and behavioural ratings of videotaped interactions.
Number of subjects: 60
Study: 26797192

Group type: EXPERIMENTAL
Intervention: Low-level light therapy using the Color DNA-WSF device
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo treatment with a dummy device
Number of subjects: 88
Study: 26405895

Group type: EXPERIMENTAL
Intervention: Hybrid flower pollination algorithm with randomized location modification
Number of subjects: 0

Group type: COMPARATOR
Intervention: State-of-the-art evolutionary algorithms (control group)
Number of subjects: 0
Study: 24002591

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (3 mg per day oral)
Number of subjects: 18
Study: 20233517

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/day)
Number of subjects: 56
Study: 17602039

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.45 mg.kg(‐1) iv (1.5 x ED(95))
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg.kg(‐1) iv (2.0 x ED(95))
Number of subjects: 84

Group type: COMPARATOR
Intervention: Saline placebo (Group 1)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Saline placebo (Group 3)
Number of subjects: 84
Study: 15449263

Group type: EXPERIMENTAL
Intervention: Levatorplasty
Number of subjects: 59

Group type: COMPARATOR
Intervention: Anal plug electrostimulation of the pelvic floor
Number of subjects: 59
Study: 11207463

Group type: EXPERIMENTAL
Intervention: Early ambulation (group A) after total regression of spinal block
Number of subjects: 107

Group type: COMPARATOR
Intervention: Late mobilisation (group B) bedridden for more than 12 h
Number of subjects: 107
Study: 9554360

Group type: EXPERIMENTAL
Intervention: Transurethral needle ablation of the prostate
Number of subjects: 121

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate
Number of subjects: 121
Study: 8059672

Group type: COMPARATOR
Intervention: 0.05 mmol/kg gadoteridol
Number of subjects: 23

Group type: COMPARATOR
Intervention: 0.1 mmol/kg gadoteridol
Number of subjects: 23

Group type: COMPARATOR
Intervention: 0.2 mmol/kg gadoteridol
Number of subjects: 23

Group type: COMPARATOR
Intervention: 0.3 mmol/kg gadoteridol
Number of subjects: 23
Study: 3057923

Group type: EXPERIMENTAL
Intervention: Clomipramine (discontinued)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30810846

Group type: EXPERIMENTAL
Intervention: S-R-S-R strategy (studying and then retrieving a text two times)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S-S/J-S-S/J strategy (studying a text four times while completing multiple JOL during the second and fourth repetitions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: S-S-S-S strategy (studying a text four times)
Number of subjects: 0
Study: 30571495

Group type: COMPARATOR
Intervention: Regularly performing no or low-intensity exercise compared with more physical activity
Number of subjects: 1424

Group type: EXPERIMENTAL
Intervention: Every SD increase in systolic blood pressure
Number of subjects: 1424

Group type: EXPERIMENTAL
Intervention: History of smoking
Number of subjects: 1424

Group type: COMPARATOR
Intervention: 5-year follow-up of PVC frequency
Number of subjects: 1424

Group type: EXPERIMENTAL
Intervention: Increased diastolic blood pressure
Number of subjects: 1424
Study: 27265451

Group type: EXPERIMENTAL
Intervention: PRP-CRM197 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: PRP-T vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRP-CRM197 vaccine with DTaP
Number of subjects: 0

Group type: COMPARATOR
Intervention: PRP-T vaccine with DTaP
Number of subjects: 0
Study: 24302608

Group type: EXPERIMENTAL
Intervention: Colestilan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0